{'fraction_non_alphanumeric': 0.04042553191489362, 'fraction_numerical': 0.02624113475177305, 'mean_word_length': 4.806584362139918, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cyclosporin A Treatment of Children with Severe Atopic Dermatitis Improves Quality of Life of Their Mothers

Background: Quality of life (QOL) in mothers of children with severe atopic dermatitis (AD) is impaired. Objective: In order to investigate whether or not clinical improvement of children’s AD by a microemulsion of cyclosporin A (CyA) is associated with changes in mothers’ QOL, a recently validated disease-specific questionnaire was employed. Methods: In an open uncontrolled study, 10 children (age 22–189 months) with severe AD (SCORAD > 50) were treated with a microemulsion of CyA for 8 weeks. Mothers’ QOL was measured before the first day of treatment as well as after 2 and 8 weeks. Objective and subjective disease activity was assessed every 2 weeks using the SCORAD index. Results: AD intensity (p = 0.005) and pruritus (p = 0.024) were significantly reduced after 2 weeks of CyA therapy and sleeping disturbances after 8 weeks (p = 0.008). Significant improvements occurred in mothers’ emotional status QOL scores at week 2 (p = 0.027). An improvement in the mothers’ psychosomatic status was seen after 8 weeks (p = 0.046). Conclusion: Our study suggests that an improved clinical status of the child with severe AD, when treated with CyA, is associated with an increased QOL in the mother. The questionnaire used in this trial is sensitive for detecting clinically relevant QOL changes.